Madrigal Pharmaceuticals heads into Wednesday's Q2 earnings report with short sellers having dramatically reduced their exposure over the past month — the starkest positioning shift heading into this print.
The retreat in short interest is the defining feature of the setup. Shorts have been cut nearly in half over the past 30 days, falling from roughly 3.8 million shares to around 2 million — an 8.6% float position that is itself 42% lower than it was just one week ago. That unwinding has loosened borrow conditions significantly: availability is now 1,379% — more than 13 shares available for every one already borrowed — with plenty of room to establish new positions at a cost-to-borrow running below 0.5%. Short pressure is not the story into this print. Options positioning tells a slightly more cautious tale, with the put/call ratio at 0.45, modestly above its 20-day average of 0.41 and running near the top of recent range, though still well below the 52-week high of 0.76. The stock itself is down 2.3% on the day and off 1.5% on the week, giving back some of a 5% monthly gain, closing at $538.80.
The bull and bear cases hinge almost entirely on the commercial trajectory of Rezdiffra, Madrigal's approved NASH therapy. Bulls point to a high unmet need in metabolic dysfunction-associated steatohepatitis, an already-demonstrated early launch demand, and the strategic depth added by the ARO-PNPLA3 licensing deal with Arrowhead for combination therapy optionality. The analyst community leans constructive: Wells Fargo initiated coverage on July 27 with an Overweight rating and a $685 target, while the consensus mean target of $680.60 implies roughly 26% upside from current levels. Bears counter that Rezdiffra faces a competitive market, that pipeline spending is stretching the balance sheet, and that BofA — sitting at Neutral with a $542 target — sees almost no upside from here. With a PE of 130x and EV/EBITDA near 77x, the valuation demands execution. Notably, both multiples have compressed meaningfully over the past 30 days as estimates have improved relative to price, suggesting the market is beginning to price in real earnings power.
One ownership detail stands out. CEO William Sibold sold approximately $1.4 million in stock on July 20, ten days before the print — a cluster of small transactions executed across multiple price points between $543 and $555. The ORTEX short score has also dropped sharply this week, from 65 ten days ago to 56.7, consistent with the short interest unwind and the relaxation of borrow pressure. Among the top institutional holders, Janus Henderson and RTW Investments together hold more than 17% of shares, while Paulson & Co trimmed its position by over 300,000 shares in the most recent reporting period — a notable reduction from one of the stock's larger holders.
The Q2 print is therefore a test of whether Rezdiffra's commercial ramp can justify a valuation that still requires considerable growth — and whether the rapid short covering of the past two weeks reflected conviction, or simply a clearing of positions ahead of event risk.
See the live data behind this article on ORTEX.
Open MDGL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
